<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Oct. 11, 2018 (HealthDay News) — Low-dose aspirin use is associated with a reduced risk for ovarian cancer, according to a study published online Oct. 4 in JAMA Oncology<\/i>.<\/p>\n
Mollie E. Barnard, Sc.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues examined nonsteroidal anti-inflammatory drug (NSAID) use and ovarian cancer diagnosis using data from two prospective cohorts: 93,664 women in the Nurses’ Health Study (NHS) and 111,834 in the NHS II.<\/p>\n
The researchers identified 1,054 cases of incident epithelial ovarian cancer among the 205,498 women in both cohorts. When current use versus non-use of any aspirin was evaluated, significant associations between aspirin and cancer risk were not observed, regardless of aspirin dose (hazard ratio, 0.99; 95 percent confidence interval, 0.83 to 1.19). On separate analysis of low-dose and standard-dose aspirin, an inverse association was identified for low-dose aspirin (hazard ratio, 0.77; 95 percent confidence interval, 0.61 to 0.96) but not for standard-dose aspirin (hazard ratio, 1.17; 95 percent confidence interval, 0.92 to 1.49). Compared with non-use, current use of non-aspirin NSAIDs correlated with ovarian cancer risk (hazard ratio, 1.19; 95 percent confidence interval, 1.00 to 1.41); there were significant positive trends for duration of use and cumulative average tablets per week (P = 0.02 and 0.03 for trend, respectively).<\/p>\n
“These results support a lower risk of ovarian cancer among low-dose aspirin users, although the association between other nonsteroidal anti-inflammatory drugs and ovarian cancer may be more complex,” the authors write.<\/p>\n
Abstract\/Full Text<\/a><\/p>\n